Bausch Health Companies Inc. (BHC)
Form 4 sales, Form 144 notices and lockup dates
- Latest sale
- $259k
- Aug 19 · Routine
- Form 4 sales
- 72
- On record
- Form 144 notices
- 6
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 144 noticeNoticeDec 2 2024
Filed to sell 440 shares ($4k)
Carson Seana, Officer
10b5-1 planFirst sale on recordFiling
- 2 Form 4 saleRoutineDec 2 same day
Sold 440 shares at $8.35 ($4k)
Carson Seana, EVP, General Counsel
10b5-1 planSold 0.1% of holdings ($3.6M position)433,066 shares leftFirst sale on recordFollows a Form 144Filing
- 3 Form 4 saleNo planAug 21 +262 days
Sold 15,912 shares at $7.66 ($122k)
Lee Frank D., Director
No 10b5-1 planSold 17.7% of holdings ($687k position)73,795 shares leftFirst sale on recordFiling
- 4 Form 4 saleUnusualSep 8 +18 days
Sold 13,370 shares at $7.31 ($98k)
Carson Seana, EVP, General Counsel
10b5-1 planSold 2.6% of holdings ($3.7M position)499,585 shares left30.4x usual sizeFiling
- 5 Form 4 saleRoutineFeb 27 +172 days
Sold 8,388 shares at $5.95 ($50k)
Carson Seana, EVP, General Counsel
10b5-1 planSold 1% of holdings ($4.9M position)809,258 shares left0.9x usual sizeFiling
- 6 Form 4 saleRoutineMar 3 +4 days
Sold 11,276 shares at $5.78 ($65k)
Carson Seana, EVP, General Counsel
10b5-1 planSold 1.8% of holdings ($3.6M position)616,761 shares left1.3x usual sizeFiling
- 7 Form 4 saleRoutineMay 19 +77 days
Sold 24,456 shares at $5.43 ($133k)
Lee Frank D., Director
10b5-1 planSold 33.1% of holdings ($401k position)49,339 shares leftFiling
- 8 Form 4 saleRoutineAug 19 +92 days
Sold 36,827 shares at $7.03 ($259k)
Lenar Aimee J., President, US Pharma
10b5-1 planSold 9.9% of holdings ($2.6M position)334,853 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales, notices and lockups (78)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Lenar Aimee J. | President, US Pharma | Form 4 sale | 36,827 | $259k | 9.9% | Routine | SEC |
| May 19, 2026 | Lee Frank D. | Director | Form 4 sale | 24,456 | $133k | 33.1% | Routine | SEC |
| Mar 3, 2026 | Carson Seana | EVP, General Counsel | Form 4 sale | 11,276 | $65k | 1.8% | Routine | SEC |
| Feb 27, 2026 | Carson Seana | EVP, General Counsel | Form 4 sale | 8,388 | $50k | 1.0% | Routine | SEC |
| Sep 8, 2025 | Carson Seana | EVP, General Counsel | Form 4 sale | 13,370 | $98k | 2.6% | Unusual | SEC |
| Aug 21, 2025 | Lee Frank D. | Director | Form 4 sale | 15,912 | $122k | 17.7% | No plan | SEC |
| Dec 2, 2024 | Carson Seana | EVP, General Counsel | Form 4 sale | 440 | $4k | 0.1% | Routine | SEC |
| Dec 2, 2024 | Carson Seana | Officer | Form 144 notice | 440 | $4k | Notice | SEC | |
| Sep 6, 2024 | Carson Seana | EVP, General Counsel | Form 4 sale | 13,370 | $83k | 3.0% | Unusual | SEC |
| Mar 4, 2024 | Carson Seana | EVP, General Counsel | Form 4 sale | 6,313 | $62k | 1.2% | Unusual | SEC |
| Mar 4, 2024 | Carson Seana | Officer | Form 144 notice | 6,313 | $62k | Notice | SEC | |
| Dec 5, 2023 | Carson Seana | EVP, General Counsel | Form 4 sale | 220 | $2k | 0.1% | Routine | SEC |
| Dec 5, 2023 | Carson Seana | Officer | Form 144 notice | 220 | $2k | Notice | SEC | |
| Nov 6, 2023 | Carson Seana | EVP, General Counsel | Form 4 sale | 43 | $327 | 0.0% | Routine | SEC |
| Nov 6, 2023 | Carson Seana | Officer | Form 144 notice | 43 | $327 | Notice | SEC | |
| Sep 6, 2023 | Carson Seana | EVP, General Counsel | Form 4 sale | 6,685 | $55k | 1.7% | Routine | SEC |
| Sep 6, 2023 | Carson Seana | Officer | Form 144 notice | 6,685 | $55k | Notice | SEC | |
| Mar 6, 2023 | Carson Seana | Officer | Form 144 notice | 495 | $5k | Notice | SEC | |
| Feb 28, 2023 | Carson Seana | EVP, General Counsel | Form 4 sale | 292 | $3k | 0.1% | Plan not stated | SEC |
| Apr 14, 2022 | Spurr Robert | U.S. President-Pharma Business | Form 4 sale | 1,595 | $35k | 1.7% | Plan not stated | SEC |
| Mar 15, 2022 | Spurr Robert | U.S. President-Pharma Business | Form 4 sale | 4,846 | $108k | 5.0% | Plan not stated | SEC |
| Mar 8, 2022 | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Form 4 sale | 3,889 | $85k | 4.0% | Plan not stated | SEC |
| Mar 2, 2022 | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Form 4 sale | 11,077 | $259k | 9.9% | Plan not stated | SEC |
| Mar 2, 2022 | Spurr Robert | U.S. President-Pharma Business | Form 4 sale | 1,595 | $37k | 2.4% | Plan not stated | SEC |
| Mar 1, 2022 | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Form 4 sale | 6,338 | $151k | 5.3% | Plan not stated | SEC |
| Feb 15, 2022 | Spurr Robert | U.S. President-Pharma Business | Form 4 sale | 3,251 | $81k | 5.1% | Plan not stated | SEC |
| Jan 18, 2022 | Spurr Robert | U.S. President-Pharma Business | Form 4 sale | 3,251 | $87k | 4.9% | Plan not stated | SEC |
| Jun 11, 2021 | Eldessouky Sam | EVP & Chief Financial Officer | Form 4 sale | 17,000 | $539k | 12.7% | Plan not stated | SEC |
| Jun 2, 2021 | Ackermann Christina | EVP AND GENERAL COUNSEL | Form 4 sale | 121,198 | $3.9M | 42.1% | Unusual | SEC |
| May 26, 2021 | Wechsler Amy B | Director | Form 4 sale | 11,037 | $351k | 10.1% | Plan not stated | SEC |
| Dec 4, 2020 | Humphries William D. | President, Ortho-Dermatologics | Form 4 sale | 114,055 | $2.3M | 32.7% | Unusual | SEC |
| Nov 27, 2020 | Humphries William D. | President, Ortho-Dermatologics | Form 4 sale | 36,804 | $722k | 13.5% | Plan not stated | SEC |
| Sep 8, 2020 | Humphries William D. | President, Ortho-Dermatologics | Form 4 sale | 5,667 | $92k | 2.4% | Plan not stated | SEC |
| Jun 5, 2020 | ValueAct Holdings II, L.P. | Director | Form 4 sale | 948,353 | $18.2M | 100.0% | Unusual | SEC |
| Aug 19, 2019 | McKenna Mark C. | President, Salix | Form 4 sale | 10,773 | $235k | 34.2% | Unusual | SEC |
| Aug 12, 2019 | Ackermann Christina | EVP AND GENERAL COUNSEL | Form 4 sale | 3,418 | $77k | 6.3% | Plan not stated | SEC |
| Jul 11, 2019 | Ackermann Christina | EVP AND GENERAL COUNSEL | Form 4 sale | 3,968 | $98k | 6.0% | Plan not stated | SEC |
| Oct 16, 2018 | Ackermann Christina | EVP AND GENERAL COUNSEL | Form 4 sale | 19,946 | $498k | 27.9% | Unusual | SEC |
| Mar 6, 2018 | Paulson John | Director | Form 4 sale | 7.1M | $109M | 33.9% | Unusual | SEC |
| Nov 16, 2017 | Paulson John | Director | Form 4 sale | 344,216 | $5M | 1.6% | Plan not stated | SEC |
| Mar 13, 2017 | PS Management GP, LLC | Director | Form 4 sale | 18.1M | $199M | 100.0% | Unusual | SEC |
| Dec 12, 2016 | Pershing Square Capital Management, L.P. | Director | Form 4 sale | 3.5M | $51.6M | 16.1% | Plan not stated | SEC |
| Nov 5, 2015 | Pearson J. Michael | Chief Executive Officer | Form 4 sale | 1.3M | $102M | 46.1% | Unusual | SEC |
| Jun 10, 2015 | ValueAct Capital Management, L.P. | Director | Form 4 sale | 4.2M | $925M | 79.9% | Unusual | SEC |
| Jun 2, 2015 | Mirovsky Pavel | EVP, Pres. & GM Valeant EMENA | Form 4 sale | 38,000 | $9M | 73.5% | Unusual | SEC |
| May 4, 2015 | Chai-Onn Robert Roswell | EVP, CLO, General Counsel | Form 4 sale | 90,938 | $20.2M | 67.8% | Unusual | SEC |
| Mar 2, 2015 | Chai-Onn Robert Roswell | EVP, CLO, General Counsel | Form 4 sale | 90,939 | $18.2M | 81.0% | Unusual | SEC |
| Jun 23, 2014 | Chai-Onn Robert Roswell | EVP, Gen. Couns. & Corp. Secy. | Form 4 sale | 10,203 | $1.2M | 29.8% | Unusual | SEC |
| Jun 2, 2014 | Mirovsky Pavel | President of Valeant Europe | Form 4 sale | 10,000 | $1.3M | 100.0% | Unusual | SEC |
| May 13, 2014 | Chai-Onn Robert Roswell | EVP, Gen. Couns. & Corp. Secy. | Form 4 sale | 10,000 | $1.3M | 29.4% | Unusual | SEC |
| Apr 1, 2014 | Provencio Norma Ann | Director | Form 4 sale | 5,000 | $661k | 3.5% | Plan not stated | SEC |
| Mar 17, 2014 | Chai-Onn Robert Roswell | EVP, Gen. Couns. & Corp. Secy. | Form 4 sale | 5,000 | $709k | 17.2% | Plan not stated | SEC |
| Mar 3, 2014 | Provencio Norma Ann | Director | Form 4 sale | 5,000 | $708k | 3.4% | Plan not stated | SEC |
| Feb 3, 2014 | Provencio Norma Ann | Director | Form 4 sale | 5,000 | $681k | 3.3% | Plan not stated | SEC |
| Jan 13, 2014 | Provencio Norma Ann | Director | Form 4 sale | 5,000 | $665k | 3.2% | Plan not stated | SEC |
| Nov 1, 2013 | Provencio Norma Ann | Director | Form 4 sale | 5,000 | $534k | 3.1% | Plan not stated | SEC |
| Sep 6, 2013 | Provencio Norma Ann | Director | Form 4 sale | 4,000 | $401k | 2.4% | Plan not stated | SEC |
| Sep 3, 2013 | Provencio Norma Ann | Director | Form 4 sale | 5,000 | $498k | 2.9% | Plan not stated | SEC |
| Jun 11, 2013 | Provencio Norma Ann | Director | Form 4 sale | 6,000 | $512k | 3.4% | Plan not stated | SEC |
| Nov 8, 2012 | De Silva Rajiv | Pres & COO, Specialty Pharm | Form 4 sale | 76,344 | $4.1M | 22.4% | Plan not stated | SEC |
| Nov 6, 2012 | De Silva Rajiv | Pres. & COO, Specialty Pharma | Form 4 sale | 220,696 | $12M | 45.4% | Unusual | SEC |
| May 10, 2012 | Masterson Richard Kevin | Pres. & COO, Valeant Intl. BB | Form 4 sale | 4 | $210 | 0.0% | Plan not stated | SEC |
| Mar 7, 2012 | Hall Susan | Global Head of R&D | Form 4 sale | 16,120 | $879k | 100.0% | Unusual | SEC |
| May 13, 2011 | VA Partners I, LLC | Director | Form 4 sale | 4.5M | $225M | 23.0% | Plan not stated | SEC |
| May 11, 2011 | Durham Mark Andrew | SVP Human Resources | Form 4 sale | 50,000 | $2.6M | 44.8% | Unusual | SEC |
| Mar 10, 2011 | ValueAct Capital Management, L.P. | Director | Form 4 sale | 7.4M | $275M | 27.3% | Unusual | SEC |
| Feb 28, 2011 | Ingram Robert Alexander | Director | Form 4 sale | 9,872 | $395k | 100.0% | Unusual | SEC |
| Dec 7, 2010 | Wells William McDowall | Director | Form 4 sale | 507,851 | $14.3M | 87.1% | Unusual | SEC |
| Dec 1, 2010 | De Silva Rajiv | President & COO Spec. Pharma. | Form 4 sale | 219,897 | $5.9M | 43.0% | Unusual | SEC |
| Nov 29, 2010 | Chouinard Michel | COO, Biovail Labs.Intl SRL | Form 4 sale | 134,908 | $3.4M | 98.2% | Unusual | SEC |
| Nov 9, 2010 | Chai-Onn Robert Roswell | EVP, GC & Corp. Sec. | Form 4 sale | 35,607 | $924k | 65.8% | Unusual | SEC |
| Nov 9, 2010 | Wells William McDowall | Director | Form 4 sale | 375,100 | $9.7M | 51.7% | Unusual | SEC |
| Aug 20, 2010 | Durham Mark Andrew | SVP, HR & Shared Services | Form 4 sale | 60,000 | $1.3M | 98.0% | Unusual | SEC |
| Aug 9, 2010 | Mayer Christine | SVP, BTA Pharmaceuticals, Inc. | Form 4 sale | 20,000 | $458k | 100.0% | Unusual | SEC |
| Jun 1, 2010 | Squires Douglas John Paul | Director | Form 4 sale | 75,033 | $1.1M | 71.7% | Unusual | SEC |
| May 11, 2010 | Chouinard Michel | CCO, Biovail Labs. Intl SRL | Form 4 sale | 12,500 | $212k | 83.5% | Unusual | SEC |
| Mar 17, 2010 | Fibiger Hans Christian | Chief Scientific Officer | Form 4 sale | 40,000 | $630k | 100.0% | Unusual | SEC |
| Mar 11, 2010 | Chouinard Michel | COO, Biovail Labs. Int'l SRL | Form 4 sale | 21,829 | $337k | 89.8% | Unusual | SEC |